vs
ICU MEDICAL INC（ICUI）与OSI SYSTEMS INC（OSIS）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是OSI SYSTEMS INC的1.2倍（$540.7M vs $464.1M），OSI SYSTEMS INC净利率更高（8.3% vs -2.9%，领先11.2%），OSI SYSTEMS INC同比增速更快（10.5% vs -14.1%），OSI SYSTEMS INC自由现金流更多（$55.5M vs $36.0M），过去两年OSI SYSTEMS INC的营收复合增速更高（7.0% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
OSI系统公司是总部位于美国加利福尼亚州的企业，主营安全检测系统、医疗设备及光电器件三大业务板块，产品涵盖机场安检X光机、金属探测器、医疗监护与麻醉系统等，旗下拥有Spacelabs Healthcare、Rapiscan Systems、OSI Optoelectronics等子公司，全球员工规模约3180人。
ICUI vs OSIS — 直观对比
营收规模更大
ICUI
是对方的1.2倍
$464.1M
营收增速更快
OSIS
高出24.7%
-14.1%
净利率更高
OSIS
高出11.2%
-2.9%
自由现金流更多
OSIS
多$19.6M
$36.0M
两年增速更快
OSIS
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $464.1M |
| 净利润 | $-15.7M | $38.7M |
| 毛利率 | 37.5% | 32.7% |
| 营业利润率 | 1.0% | 12.7% |
| 净利率 | -2.9% | 8.3% |
| 营收同比 | -14.1% | 10.5% |
| 净利润同比 | 34.0% | 2.3% |
| 每股收益（稀释后） | $-0.63 | $2.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIOSIS
| Q4 25 | $540.7M | $464.1M | ||
| Q3 25 | $537.0M | $384.6M | ||
| Q2 25 | $548.9M | $505.0M | ||
| Q1 25 | $604.7M | $444.4M | ||
| Q4 24 | $629.8M | $419.8M | ||
| Q3 24 | $589.1M | $344.0M | ||
| Q2 24 | $596.5M | $480.9M | ||
| Q1 24 | $566.7M | $405.4M |
净利润ICUIOSIS
| Q4 25 | $-15.7M | $38.7M | ||
| Q3 25 | $-3.4M | $20.6M | ||
| Q2 25 | $35.3M | $52.7M | ||
| Q1 25 | $-15.5M | $41.1M | ||
| Q4 24 | $-23.8M | $37.8M | ||
| Q3 24 | $-33.0M | $17.9M | ||
| Q2 24 | $-21.4M | $44.7M | ||
| Q1 24 | $-39.5M | $34.0M |
毛利率ICUIOSIS
| Q4 25 | 37.5% | 32.7% | ||
| Q3 25 | 37.4% | 32.0% | ||
| Q2 25 | 37.9% | 33.3% | ||
| Q1 25 | 34.7% | 33.8% | ||
| Q4 24 | 36.1% | 35.1% | ||
| Q3 24 | 34.8% | 35.3% | ||
| Q2 24 | 34.8% | 32.1% | ||
| Q1 24 | 32.7% | 33.6% |
营业利润率ICUIOSIS
| Q4 25 | 1.0% | 12.7% | ||
| Q3 25 | 2.6% | 8.6% | ||
| Q2 25 | 1.9% | 14.5% | ||
| Q1 25 | 2.1% | 12.7% | ||
| Q4 24 | 6.0% | 13.8% | ||
| Q3 24 | 1.4% | 8.8% | ||
| Q2 24 | 1.3% | 13.1% | ||
| Q1 24 | -1.9% | 12.7% |
净利率ICUIOSIS
| Q4 25 | -2.9% | 8.3% | ||
| Q3 25 | -0.6% | 5.3% | ||
| Q2 25 | 6.4% | 10.4% | ||
| Q1 25 | -2.6% | 9.3% | ||
| Q4 24 | -3.8% | 9.0% | ||
| Q3 24 | -5.6% | 5.2% | ||
| Q2 24 | -3.6% | 9.3% | ||
| Q1 24 | -7.0% | 8.4% |
每股收益（稀释后）ICUIOSIS
| Q4 25 | $-0.63 | $2.22 | ||
| Q3 25 | $-0.14 | $1.18 | ||
| Q2 25 | $1.43 | $3.04 | ||
| Q1 25 | $-0.63 | $2.40 | ||
| Q4 24 | $-0.97 | $2.22 | ||
| Q3 24 | $-1.35 | $1.05 | ||
| Q2 24 | $-0.88 | $2.57 | ||
| Q1 24 | $-1.63 | $1.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $336.7M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $2.1B | $845.5M |
| 总资产 | $4.1B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 1.19× |
8季度趋势，按日历期对齐
现金及短期投资ICUIOSIS
| Q4 25 | — | $336.7M | ||
| Q3 25 | — | $124.4M | ||
| Q2 25 | — | $106.4M | ||
| Q1 25 | — | $95.8M | ||
| Q4 24 | $308.6M | $101.6M | ||
| Q3 24 | $312.5M | $85.1M | ||
| Q2 24 | $302.6M | $95.4M | ||
| Q1 24 | $251.4M | $101.4M |
总债务ICUIOSIS
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $442.2M | ||
| Q2 25 | — | $471.6M | ||
| Q1 25 | — | $473.2M | ||
| Q4 24 | — | $474.8M | ||
| Q3 24 | — | $476.3M | ||
| Q2 24 | — | $137.6M | ||
| Q1 24 | — | — |
股东权益ICUIOSIS
| Q4 25 | $2.1B | $845.5M | ||
| Q3 25 | $2.1B | $946.0M | ||
| Q2 25 | $2.1B | $951.1M | ||
| Q1 25 | $2.0B | $879.3M | ||
| Q4 24 | $2.0B | $825.8M | ||
| Q3 24 | $2.0B | $786.5M | ||
| Q2 24 | $2.0B | $863.5M | ||
| Q1 24 | $2.1B | $813.4M |
总资产ICUIOSIS
| Q4 25 | $4.1B | $2.5B | ||
| Q3 25 | $4.1B | $2.3B | ||
| Q2 25 | $4.1B | $2.2B | ||
| Q1 25 | $4.2B | $2.1B | ||
| Q4 24 | $4.2B | $2.1B | ||
| Q3 24 | $4.3B | $2.1B | ||
| Q2 24 | $4.3B | $1.9B | ||
| Q1 24 | $4.3B | $1.8B |
负债/权益比ICUIOSIS
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.57× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $62.2M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $55.5M |
| 自由现金流率自由现金流/营收 | 6.6% | 12.0% |
| 资本支出强度资本支出/营收 | 4.6% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 1.61× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $137.2M |
8季度趋势，按日历期对齐
经营现金流ICUIOSIS
| Q4 25 | $60.6M | $62.2M | ||
| Q3 25 | $56.7M | $17.1M | ||
| Q2 25 | $11.2M | $562.0K | ||
| Q1 25 | $51.3M | $81.6M | ||
| Q4 24 | $40.2M | $52.5M | ||
| Q3 24 | $36.1M | $-37.2M | ||
| Q2 24 | $82.0M | $-29.0M | ||
| Q1 24 | $45.8M | $-52.1M |
自由现金流ICUIOSIS
| Q4 25 | $36.0M | $55.5M | ||
| Q3 25 | $27.6M | $10.1M | ||
| Q2 25 | $-8.5M | $-5.6M | ||
| Q1 25 | $36.7M | $77.1M | ||
| Q4 24 | $16.1M | $47.1M | ||
| Q3 24 | $16.2M | $-44.9M | ||
| Q2 24 | $62.5M | $-37.5M | ||
| Q1 24 | $29.9M | $-57.0M |
自由现金流率ICUIOSIS
| Q4 25 | 6.6% | 12.0% | ||
| Q3 25 | 5.1% | 2.6% | ||
| Q2 25 | -1.5% | -1.1% | ||
| Q1 25 | 6.1% | 17.4% | ||
| Q4 24 | 2.6% | 11.2% | ||
| Q3 24 | 2.7% | -13.0% | ||
| Q2 24 | 10.5% | -7.8% | ||
| Q1 24 | 5.3% | -14.1% |
资本支出强度ICUIOSIS
| Q4 25 | 4.6% | 1.4% | ||
| Q3 25 | 5.4% | 1.8% | ||
| Q2 25 | 3.6% | 1.2% | ||
| Q1 25 | 2.4% | 1.0% | ||
| Q4 24 | 3.8% | 1.3% | ||
| Q3 24 | 3.4% | 2.2% | ||
| Q2 24 | 3.3% | 1.8% | ||
| Q1 24 | 2.8% | 1.2% |
现金转化率ICUIOSIS
| Q4 25 | — | 1.61× | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | 0.32× | 0.01× | ||
| Q1 25 | — | 1.98× | ||
| Q4 24 | — | 1.39× | ||
| Q3 24 | — | -2.07× | ||
| Q2 24 | — | -0.65× | ||
| Q1 24 | — | -1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
OSIS
| Security Division | $334.7M | 72% |
| Optoelectronics And Manufacturing Division | $92.8M | 20% |
| Healthcare Division | $36.5M | 8% |
